SeekingAlpha · Aug 14, 2026
FB
NASDAQ · FBRX
Forte Biosciences, Inc.
Healthcare · Biotechnology
$76.99
Up+$0.00 (+0.00%)
Updated Nov 4, 2026, 10:02 AM
SID Score
5.3/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 284.11M
- P/E ratio
- -7.8
- Dividend yield
- 0.00%
- 52-week range
- $15.51 – $77.20
- Volume
- 1.4M
- Avg. volume
- 102.85K
Price performance · FBRX
FBRX price history
1M range · 0 trading sessions · Daily adjusted prices
FBRX does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest FBRX news
The latest Smart Investors Daily articles mentioning FBRX.
Stock researchCompany · Overview
Company
Market Activity
Research & News
FBRX research
Overview
Company profile and research snapshot.
Company profile
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $65.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 28, 2026 | Barclays | Equal-Weight | — |
| Jul 21, 2026 | Barclays | Overweight | — |
| Nov 25, 2025 | Evercore ISI Group | Outperform | — |
| Nov 17, 2025 | Chardan Capital | Buy | — |
| Aug 18, 2025 | Guggenheim | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Aug 6, 2026
Alger Small Cap Focus Fund Q2 2026 Portfolio Review
Nebius Group, Credo Technology Group, and Guardant Health, Inc. were among the top contributors to performance.
Benzinga · Aug 6, 2026
argenx Commences $77/Shr Cash Tender Offer Through Subsidiary Avena Merger Sub To Acquire All Outstanding Shares Of Forte Biosciences
argenx ((Euronext &, NASDAQ:ARGX), a global immunology innovation company today announced that Avena Merger Sub Inc. ("Purchaser"), a wholly-owned subsidiary of argenx BV ("argenx"), has commenced a
Benzinga · Jul 28, 2026
Barclays Downgrades Forte Biosciences to Equal-Weight, Raises Price Target to $77
Barclays analyst Etzer Darout downgrades Forte Biosciences (NASDAQ:FBRX) from Overweight to Equal-Weight and raises the price target from $74 to $77.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
